🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 19 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/01/2016 11,22 11,26 10,87 11,00 -1,79% 3,48% 9.412
25/01/2016 10,76 11,20 10,70 11,20 +6,16% 4,65% 16.056
22/01/2016 10,55 10,60 10,40 10,55 +0,57% 1,90% 8.994
21/01/2016 10,82 10,82 10,40 10,49 +1,55% 3,88% 9.518
20/01/2016 10,91 10,91 10,31 10,33 -4,26% 5,50% 6.350
19/01/2016 10,49 10,80 10,33 10,79 +2,86% 4,48% 5.207
18/01/2016 10,40 10,75 10,25 10,49 +0,87% 4,81% 8.475
15/01/2016 10,64 10,65 10,40 10,40 -2,16% 2,35% 7.965
14/01/2016 10,80 10,80 10,51 10,63 -1,57% 2,69% 5.650
13/01/2016 10,68 11,03 10,65 10,80 +1,22% 3,56% 7.941
12/01/2016 10,83 10,84 10,55 10,67 -0,56% 2,68% 24.020
11/01/2016 10,71 10,73 10,61 10,73 +0,47% 1,12% 64.001
08/01/2016 10,96 11,10 10,66 10,68 -1,84% 4,01% 3.862
07/01/2016 11,45 11,45 10,75 10,88 -5,31% 6,11% 12.577
06/01/2016 11,43 11,58 11,19 11,49 +4,36% 3,41% 8.404
05/01/2016 11,20 11,30 11,01 11,01 -1,70% 2,59% 7.876
04/01/2016 11,14 11,20 11,00 11,20 +1,63% 1,80% 2.954
30/12/2015 11,29 11,29 11,00 11,02 -2,30% 2,57% 5.099
29/12/2015 11,00 11,35 11,00 11,28 +3,87% 3,18% 7.962
28/12/2015 10,64 11,09 10,64 10,86 +4,12% 4,23% 19.459
24/12/2015 10,43 10,59 10,40 10,43 +0,29% 1,82% 4.770
23/12/2015 10,29 10,42 10,14 10,40 +1,86% 2,72% 5.631
22/12/2015 10,20 10,31 10,10 10,21 +0,49% 2,06% 2.183
21/12/2015 10,30 10,49 10,07 10,16 +1,50% 4,08% 7.424
18/12/2015 10,04 10,15 10,00 10,01 +0,00% 1,49% 9.456
17/12/2015 10,07 10,30 10,00 10,01 +0,30% 2,98% 43.077
16/12/2015 9,88 9,99 9,65 9,98 +1,32% 3,44% 11.419
15/12/2015 9,84 9,86 9,70 9,85 +1,03% 1,63% 3.060
14/12/2015 9,83 9,83 9,65 9,75 +0,00% 1,83% 2.987
11/12/2015 9,79 9,80 9,70 9,75 +0,00% 1,02% 910